The AstraZeneca jab is the cheapest of the main Covid-19 vaccines, priced at just $2.15 a dose in the company’s contract with the EU, rising to just over $5 a shot elsewhere. Results from clinical trials are expected later this year. The UK government is in negotiations with AstraZeneca to order a new version of its vaccine adapted to tackle variants of the coronavirus. So far it has shipped 1bn doses globally and is aiming to produce a total of 2bn-3bn jabs this year.
Revenue of $1.2bn was achieved by AstraZeneca from the vaccine it developed with the University of Oxford in the first half of the year. The firm has reportedly lifted the price it charges the EU to $25.50 a dose from about $19 in its first deal. Last week the company also said that sales under the Covax vaccine initiative to low-income countries were “considerably lower than the price to the US government”. It has charged the US government (which helped fund the development of the vaccine) up to $16.50 a dose, and has sold it for $22 to $37 outside the US. It expects to produce up to 1bn jabs this year, followed by 2bn-3bn in 2022. Moderna has signed $20bn worth of vaccine contracts this year, including that for 17m doses to the UK, 460m to the EU and 500m to the US. This company generated nearly $6bn of sales from its Covid-19 vaccine in the first half of the year, achieving a $4bn net profit – the first half-year profit since the firm was founded in Massachusetts in 2010. “This means wealthier nations would pay about the cost of a takeaway meal for each dose … middle-income countries would pay roughly half that price … and to low-income countries we were offering them doses at cost.” Moderna Pfizer’s chief executive, Albert Bourla, recently explained the tiered pricing. The UK is also reportedly paying more than previously, about £22 a shot for 35m doses for next year’s autumn booster campaign. They are now charging the EU €19.50 per jab, up from €15.50 in the first procurement deal, the Financial Times reported. Pfizer and BioNTech are aiming to produce 3bn jabs this year and 4bn next year. The US government has ordered 700m up to April next year for Americans, as well as 500m for donations to the poorest nations. The two firms have agreed to supply up to 1.8bn doses to the EU from December up to 2023, on top of 600m doses previously ordered this year. In July it lifted its 2021 sales forecast to $33.5bn.īioNTech expects to make revenues of nearly €16bn (£13.5bn) from the vaccine this year, as its first-half net profit jumped to almost €4bn from €142m a year earlier.
Sales worth $11.3bn (£8bn) were made by Pfizer in the first half of this year from the Covid-19 jab that it developed with Germany’s BioNTech.
0 kommentar(er)
